Cancer research (IMAGE)
Caption
Patients with a type of high-risk blood cancer are likely to do better if no trace of the cancer is detectable before they receive donor blood cells. The finding in JAMA Oncology emphasizes the importance of testing for lingering cancer cells in the body after people receive apparently successful chemotherapy treatment. “The good news is this testing is doable,” said Christopher Hourigan, director of the Fralin Biomedical Research Institute Cancer Research Center in Washington, D.C.
Credit
Clayton Metz/Virginia Tech
Usage Restrictions
None
License
Original content